Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Squamous Cell Carcinoma of Head and Neck 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Sezary Syndrome 1Osteosarcoma 1Neuroblastoma 1Mycosis Fungoides 1Leukemia, Myeloid, Acute 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Brain Neoplasms 1

Interventions

pembrolizumab 139Cisplatin 76Cetuximab 53Carboplatin 49Paclitaxel 39Nivolumab 39Radiotherapy 37Docetaxel 34Radiotherapy, Intensity-Modulated 30Magnetic Resonance Spectroscopy 25Specimen Handling 20Fluorouracil 20Platinum 141,2-diaminocyclohexaneplatinum II citrate 13Taxes 12cemiplimab 11Radiation 11Ipilimumab 11atezolizumab 10Surgical Procedures, Operative 10Drug Therapy 10tislelizumab 9Biopsy 9durvalumab 8Radiosurgery 8Albumin-Bound Paclitaxel 8130-nm albumin-bound paclitaxel 8Standard of Care 7Chemoradiotherapy 7Immune Checkpoint Inhibitors 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × magrolimab × 1 year × Clear all
NCT04854499 2025-11-19

ELEVATE HNSCC

Gilead Sciences

Phase 2 Terminated
193 enrolled 27 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06046482 2025-10-22

Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma

M.D. Anderson Cancer Center

Phase 2 Terminated
4 enrolled 11 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon âš¡